Kevin Kunzmann

A new study shows consistent confidence and anxiety of self-care with the injectable biologic in patients with asthma.

Greater BMI scores are linked to longer ventilator needs and higher risk of acute respiratory distress syndrome.

An assessment of a combined pharmacologic and cognitive behavioral therapy program shows patients improve FEV1, FVC, and other metrics.

New cohort data comparing the lone regulated IPF therapies show one is associated with reduced mortality—while the other has a better continuation of care.

Despite being advised in clinical guidelines, fewer than 2% of COPD patients initiate pulmonary rehabilitation within 90 days of hospitalization.

How community, prevention, and research-based practice could be influenced by the pandemic.

Panagis Galiatsatos, MD, MHS, joins to discuss the underlying issues and potential solutions to COVID-19 patient disparities.

Why the virus is burdening US populations similar to other diseases.

The dermatologist fields questions on possible symptoms and signs of infection that his colleagues have observed.

The Florida-based clinician shares perspective and insight into what should be prioritized or revised in specialty care.

An assessment of survey data show patients with severe depressive or psychological symptoms are more likely to be dissatisfied with their dermatologist.

Enjoy our archived discussion between 4 experts on how their specialty is most affected by the pandemic.

The injection therapy has shown capability to stop or even reverse the progression of early puberty in patients with the rare disease.

A systematic review and meta-analysis show the systemic therapies, as well as a couple investigational biologics, may be superior.

The subcuntaenous therapy's base drug was approval for two separate multiple myeloma indications last year.

Children born to mothers who suffered from depression during pregnancy are at a greater risk of adolescent depression and psychosis.

A meta-analysis of the online CBT programs shows promising benefits, with the addition of anonymity for patients.

An expert projects annual national prevention lifeline calls will reach 3.7 million by 2023.

An analysis of 20-year outpatient prescribing trends show the drug class is being favored over mood stabilizers.

A look at how the antibody influences the pathology of encephalitis, and how it can be properly assessed and treated.

Investigators are still looking into the immediate and longterm effects of the virus on the mind.

Substance use is common in as many as 10% of pregnant women in the US. What are the risks of each substances, and what are the proven methods of treatment?

How do comorbidities influence patients' life expectancies? What is the role of public health programs?

Why the field lacks behind in effective diagnostic tools, which could better inform tailored therapy.

The novel target therapy has reported promising early findings. What is its potential?

How have natural-cause mortality rates changed over time in an international population?

How psychiatry can catch up to other specialties in accurate, timely diagnostics based on molecular breakthrough.

SEP-363856 is showing initial efficacy and long-term safety in adult patients.

A public health expert shares insight on the positives and pitfalls learned from stigma-reduction campaigns.

The free webinar, "Derm Clinical Updates: Keeping Up with COVID-19," will feature a four-expert panel fielding topics on therapies, immunocompromised patients, telemedicine, surgery, and more.